Page 49 - FBL AR 2019-20

Corporate Statutory FinanCial
overview StatementS StatementS

Overview Key highlights, FY 2019-20
For more than six decades, the Company Phenyramidol offers an attractive and
focused on the manufacture of Specialty unique proposition of addressing the
APIs and biocatalysts. Apart from Vitamin therapeutic gap in the muscle relaxant
D3, the Company produces Phenyramidol segment. Phenyramidol’ s ideal safety
and Silicon Dioxide products as a part of its profile along with its usage history
pharmaceuticals business. establishes a strong case of safety of the
molecule.
The Company’s core strength lies in
harnessing cutting-edge technologies Phenyramidol formulation tablets and
to manufacture quality APIs. Fermenta injectables are registered as muscle
is respected for its ability to optimise relaxants in Turkey since 1970, a leader in
synthetic routes for pharmaceutical this therapeutic segment. The formulation
compounds. During the year under review, has also been registered in Nigeria for five
the overall consumption remained stable. years.
Fermenta produced Phenyramidol and The market for Phenyramidol indicates
Silicon powder based on the contractual promising opportunities in view of a
customer requirement, which increased steady rise in the incidence of low back
capacity utilisation. pain as well as neck and shoulder pain
mainly due to the excessive time spent
on electronic devices and compromised
seating habits. The Company’s business is
optimistic of prospects.

10%

Share of overall revenues,
FY 2019-20

47